ATE267594T1 - Verwendung von albuminstabilisiertem paclitaxel zur herstellung eines arzneimittels zum behandeln von festen tumoren und das so erhaltene arzneimittel - Google Patents

Verwendung von albuminstabilisiertem paclitaxel zur herstellung eines arzneimittels zum behandeln von festen tumoren und das so erhaltene arzneimittel

Info

Publication number
ATE267594T1
ATE267594T1 AT01110509T AT01110509T ATE267594T1 AT E267594 T1 ATE267594 T1 AT E267594T1 AT 01110509 T AT01110509 T AT 01110509T AT 01110509 T AT01110509 T AT 01110509T AT E267594 T1 ATE267594 T1 AT E267594T1
Authority
AT
Austria
Prior art keywords
medicinal product
solid tumors
album
production
treating solid
Prior art date
Application number
AT01110509T
Other languages
English (en)
Inventor
Marco Falciani
Original Assignee
Acs Dobfar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11445079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE267594(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acs Dobfar Spa filed Critical Acs Dobfar Spa
Application granted granted Critical
Publication of ATE267594T1 publication Critical patent/ATE267594T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01110509T 2000-05-18 2001-04-27 Verwendung von albuminstabilisiertem paclitaxel zur herstellung eines arzneimittels zum behandeln von festen tumoren und das so erhaltene arzneimittel ATE267594T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2000MI001107A ITMI20001107A1 (it) 2000-05-18 2000-05-18 Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel

Publications (1)

Publication Number Publication Date
ATE267594T1 true ATE267594T1 (de) 2004-06-15

Family

ID=11445079

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01110509T ATE267594T1 (de) 2000-05-18 2001-04-27 Verwendung von albuminstabilisiertem paclitaxel zur herstellung eines arzneimittels zum behandeln von festen tumoren und das so erhaltene arzneimittel

Country Status (22)

Country Link
US (1) US6652884B2 (de)
EP (1) EP1155692B1 (de)
JP (1) JP2001354559A (de)
KR (2) KR20010105248A (de)
CN (1) CN1198609C (de)
AT (1) ATE267594T1 (de)
AU (1) AU781517B2 (de)
BR (1) BR0102040A (de)
CA (1) CA2345482A1 (de)
DE (1) DE60103453T2 (de)
DK (1) DK1155692T3 (de)
ES (1) ES2221874T3 (de)
HU (1) HU229909B1 (de)
IL (1) IL142674A0 (de)
IT (1) ITMI20001107A1 (de)
MX (1) MXPA01004980A (de)
NO (1) NO330511B1 (de)
NZ (1) NZ511201A (de)
PT (1) PT1155692E (de)
RU (1) RU2270003C2 (de)
TR (1) TR200101353A2 (de)
ZA (1) ZA200103755B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
CN1925874B (zh) * 2002-12-09 2014-12-17 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
LT1585548T (lt) * 2002-12-09 2018-09-25 Abraxis Bioscience, Llc Farmakologinių agentų kompozicijos ir įvedimo būdai
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
NZ595313A (en) 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
CA2880727C (en) 2005-08-31 2019-05-07 Neil P. Desai Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
KR101643416B1 (ko) 2005-08-31 2016-07-27 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법
US20100166872A1 (en) * 2005-10-21 2010-07-01 Amarjit Singh Novel improved compositions for cancer therapy
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
CA2672618C (en) 2006-12-14 2021-03-02 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
KR20150002886A (ko) 2007-03-07 2015-01-07 아브락시스 바이오사이언스, 엘엘씨 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
EP3326630A3 (de) * 2007-05-03 2018-08-29 Abraxis BioScience, LLC Verfahren und zusammensetzungen zur behandlung pulmonaler hypertonie
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
WO2009126401A1 (en) * 2008-04-10 2009-10-15 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
KR101090505B1 (ko) * 2008-12-30 2011-12-06 최은아 난담반을 포함하는 암 예방 및 치료용 조성물
PT2419732T (pt) 2009-04-15 2019-12-24 Abraxis Bioscience Llc Composições e métodos de nanopartículas isentas de priões
PL2552438T3 (pl) 2010-03-26 2016-12-30 Sposoby leczenia raka wątrobowokomórkowego
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
BR112012024590A2 (pt) 2010-03-29 2016-05-31 Abraxis Bioscience Inc métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
JP6257324B2 (ja) 2010-06-04 2018-01-10 アブラクシス バイオサイエンス， エルエルシー 膵臓がんの処置方法
CA3063641A1 (en) 2011-04-28 2012-11-01 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
SMT201900502T1 (it) 2011-12-14 2019-11-13 Abraxis Bioscience Llc Uso di eccipienti polimerici per la liofilizzazione o il congelamento di particelle
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
JP6349381B2 (ja) 2013-03-12 2018-06-27 アブラクシス バイオサイエンス， エルエルシー 肺がんを処置する方法
US20160015817A1 (en) * 2013-03-13 2016-01-21 Abraxis Bioscience, Llc Methods of treatment of pediatric solid tumor
NZ630213A (en) 2013-03-14 2017-05-26 Abraxis Bioscience Llc Methods of treating bladder cancer
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
JP6987644B2 (ja) 2015-06-29 2022-01-05 アブラクシス バイオサイエンス， エルエルシー 類上皮細胞腫瘍を処置する方法
EP3505183B1 (de) 2016-08-26 2022-03-30 Tetsuji Okuno Mittel zur verringerung des mikrovaskulären blutflusses und dessen verwendung
TWI660728B (zh) 2018-02-09 2019-06-01 國立交通大學 胺基喹唑啉衍生物及其醫藥組合物與用途
RU2020134124A (ru) 2018-03-20 2022-04-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ
WO2021086946A1 (en) 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
CN120919082A (zh) * 2025-10-16 2025-11-11 天津医科大学总医院 一种负载蛋白药物的GelMA微球、制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5498421A (en) 1993-02-22 1996-03-12 Vivorx Pharmaceuticals, Inc. Composition useful for in vivo delivery of biologics and methods employing same
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
KR100904931B1 (ko) * 1997-06-27 2009-06-29 아브락시스 바이오사이언스, 엘엘씨 나노 입자 및 그의 제조 방법
WO2000006152A1 (en) 1998-07-30 2000-02-10 Novopharm Biotech, Inc. Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin

Also Published As

Publication number Publication date
HUP0102039A2 (hu) 2002-05-29
HUP0102039A3 (en) 2002-12-28
DE60103453D1 (de) 2004-07-01
TR200101353A3 (tr) 2001-12-21
HK1040368A1 (en) 2002-06-07
CN1324613A (zh) 2001-12-05
DE60103453T2 (de) 2005-06-23
NZ511201A (en) 2002-11-26
IL142674A0 (en) 2002-03-10
US20010046961A1 (en) 2001-11-29
MXPA01004980A (es) 2002-08-06
BR0102040A (pt) 2002-03-19
JP2001354559A (ja) 2001-12-25
EP1155692A1 (de) 2001-11-21
DK1155692T3 (da) 2004-08-09
AU3876501A (en) 2001-11-22
HU0102039D0 (en) 2001-07-30
NO20012409D0 (no) 2001-05-16
EP1155692B1 (de) 2004-05-26
ZA200103755B (en) 2001-11-15
CA2345482A1 (en) 2001-11-18
NO20012409L (no) 2001-11-19
RU2270003C2 (ru) 2006-02-20
HU229909B1 (en) 2014-12-29
US6652884B2 (en) 2003-11-25
ES2221874T3 (es) 2005-01-16
AU781517B2 (en) 2005-05-26
NO330511B1 (no) 2011-05-09
CN1198609C (zh) 2005-04-27
KR20080091747A (ko) 2008-10-14
KR20010105248A (ko) 2001-11-28
TR200101353A2 (tr) 2001-12-21
ITMI20001107A1 (it) 2001-11-18
ITMI20001107A0 (it) 2000-05-18
PT1155692E (pt) 2004-09-30

Similar Documents

Publication Publication Date Title
ATE267594T1 (de) Verwendung von albuminstabilisiertem paclitaxel zur herstellung eines arzneimittels zum behandeln von festen tumoren und das so erhaltene arzneimittel
CY1122659T1 (el) Ενωση 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτης για μη-νοηματικη καταστολη και τη θεραπεια ασθενειας
DE69534130D1 (de) Verbindungen zur behandlung von erkrankungen,die mit des vasculogenese und/oder angiogenese in verbunden stehen.
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
ATE533458T1 (de) Anlage zum automatischen herstellen von verpackungen für medizinische und/oder pharmazeutische und/oder nahrungsergänzende produkte
DE60010702D1 (de) Behandlung von titanerz zur herstellung von titandioxidpigmenten
DE69921178D1 (de) Hapten-träger-konjugate zur behandlung und vorbeugung von nikotinabhängigkeit
ATE134507T1 (de) Mikroverkapseltes sonnenschutzmittel, das verfahren zur herstellung, kosmetische und pharmazeutische zubereitungen mit mikrokapseln und verwendung derselben
DE69735851D1 (de) Verfahren zur aktivierung von menschlichen, antigen-aktivierenden zellen, aktivierte menschliche, antigen-aktivierende zellen und anwendungen derselben
RU2001113688A (ru) Применение паклитаксела, стабилизированного альбумином, для изготовления лекарственного средства для лечения солидных опухолей и лекарственное средство, полученное указанным способом
SE9401406L (sv) Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma
DE60230869D1 (de) 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
ATE269078T1 (de) Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
DE60205894D1 (de) 4-(phenyl-piperidin-4-ylidenmethyl)-benzamid-derivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
ATE339202T1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
DE69620027D1 (de) Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs
DE3768150D1 (de) Verwendung eines 1,3-oxazolidin-2-on-derivates zur herstellung eines arzneimittels zur behandlung von ischaemie.
ATE143809T1 (de) Placentaextrakt und verfahren zu seiner herstellung
DE60202679D1 (de) 4-(phenylpiperidin-4-ylidenmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
DE60208192D1 (de) 4-(phenyl(piperidin-4-yl)amino) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
DE60208193D1 (de) 4-(phenyl(piperidin-4-yl)amino) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
ATE226956T1 (de) Alpha-d-xylose verbindungen, herstellung und verwendung als arzneimitteln
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1155692

Country of ref document: EP

EEIH Change in the person of patent owner
EEIH Change in the person of patent owner